APO RESEARCH · REPORT
Deferasirox
Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta- thalassemia and other chronic anemias.
Product & engineering
Understand the product.
Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta- thalassemia and other chronic anemias.
Deferasirox is marketed as Exjade, Desirox, Defrijet, Desifer, and Jadenu.
The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which is subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
Selected research
Market Analysis & Forecast
Global Deferasirox Market Analysis and Forecast 2026-2032
Market perspective
Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta- thalassemia and other chronic anemias.
Deferasirox is marketed as Exjade, Desirox, Defrijet, Desifer, and Jadenu.
The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which is subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
Read the full market overview
The major global manufacturers of Dillaros are Novartis, Cipla, Natco Pharma and Sun Pharma, among which Novartis is the industry leader with a market share of around 99%. North America is the largest spending region, with 30 per cent of the market, followed by Europe with 25 per cent.
This report presents an overview of global market for Deferasirox, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Deferasirox, also provides the sales of main regions and countries. Of the upcoming market potential for Deferasirox, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Deferasirox sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Deferasirox market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Deferasirox sales, projected growth trends, production technology, application and end-user industry.
Deferasirox Segment by Company
Novartis
Cipla
Natco Pharma
Sun Pharma
Deferasirox Segment by Type
500 mg/Tablet
250 mg/Tablet
125 mg/Tablet
Others
Deferasirox Segment by Application
Transfusional Iron Overload
NTDT Caused Iron Overload
Deferasirox Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Deferasirox market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Deferasirox and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Deferasirox.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Deferasirox in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Deferasirox manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Deferasirox sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 500 mg/Tablet
- 250 mg/Tablet
- 125 mg/Tablet
- Others
Applications
- Transfusional Iron Overload
- NTDT Caused Iron Overload
Companies covered
- Novartis
- Cipla
- Natco Pharma
- Sun Pharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Deferasirox Market by Type
- 1.2.1 Global Deferasirox Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 500 mg/Tablet
- 1.2.3 250 mg/Tablet
- 1.2.4 125 mg/Tablet
- 1.2.5 Others
- 1.3 Deferasirox Market by Application
- 1.3.1 Global Deferasirox Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Transfusional Iron Overload
- 1.3.3 NTDT Caused Iron Overload
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Deferasirox Market Dynamics
- 2.1 Deferasirox Industry Trends
- 2.2 Deferasirox Industry Drivers
- 2.3 Deferasirox Industry Opportunities and Challenges
- 2.4 Deferasirox Industry Restraints
3 Global Market Growth Prospects
- 3.1 Global Deferasirox Revenue Estimates and Forecasts (2021-2032)
- 3.2 Global Deferasirox Revenue by Region
- 3.2.1 Global Deferasirox Revenue by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Deferasirox Revenue by Region (2021-2026)
- 3.2.3 Global Deferasirox Revenue by Region (2027-2032)
- 3.2.4 Global Deferasirox Revenue Market Share by Region (2021-2032)
- 3.3 Global Deferasirox Sales Estimates and Forecasts 2021-2032
- 3.4 Global Deferasirox Sales by Region
- 3.4.1 Global Deferasirox Sales by Region: 2021 VS 2025 VS 2032
- 3.4.2 Global Deferasirox Sales by Region (2021-2026)
- 3.4.3 Global Deferasirox Sales by Region (2027-2032)
- 3.4.4 Global Deferasirox Sales Market Share by Region (2021-2032)
- 3.5 US & Canada & Mexico
- 3.6 Europe
- 3.7 China
- 3.8 Asia (Excluding China)
- 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
- 4.1 Global Deferasirox Revenue by Manufacturers
- 4.1.1 Global Deferasirox Revenue by Manufacturers (2021-2026)
- 4.1.2 Global Deferasirox Revenue Market Share by Manufacturers (2021-2026)
- 4.1.3 Global Deferasirox Manufacturers Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Deferasirox Sales by Manufacturers
- 4.2.1 Global Deferasirox Sales by Manufacturers (2021-2026)
- 4.2.2 Global Deferasirox Sales Market Share by Manufacturers (2021-2026)
- 4.2.3 Global Deferasirox Manufacturers Sales Share Top 10 and Top 5 in 2025
- 4.3 Global Deferasirox Sales Price by Manufacturers (2021-2026)
- 4.4 Global Deferasirox Key Manufacturers Ranking, 2024 VS 2025 VS 2026
- 4.5 Global Deferasirox Key Manufacturers Manufacturing Sites & Headquarters
- 4.6 Global Deferasirox Manufacturers, Product Type & Application
- 4.7 Global Deferasirox Manufacturers' Establishment Date
- 4.8 Market Competitive Analysis
- 4.8.1 Global Deferasirox Market CR5 and HHI
- 4.8.2 2025 Deferasirox Tier 1, Tier 2, and Tier 3
5 Deferasirox Market by Type
- 5.1 Global Deferasirox Revenue by Type
- 5.1.1 Global Deferasirox Revenue by Type (2021 VS 2025 VS 2032)
- 5.1.2 Global Deferasirox Revenue by Type (2021-2032) & (US$ Million)
- 5.1.3 Global Deferasirox Revenue Market Share by Type (2021-2032)
- 5.2 Global Deferasirox Sales by Type
- 5.2.1 Global Deferasirox Sales by Type (2021 VS 2025 VS 2032)
- 5.2.2 Global Deferasirox Sales by Type (2021-2032) & (M Tablets)
- 5.2.3 Global Deferasirox Sales Market Share by Type (2021-2032)
- 5.3 Global Deferasirox Price by Type
6 Deferasirox Market by Application
- 6.1 Global Deferasirox Revenue by Application
- 6.1.1 Global Deferasirox Revenue by Application (2021 VS 2025 VS 2032)
- 6.1.2 Global Deferasirox Revenue by Application (2021-2032) & (US$ Million)
- 6.1.3 Global Deferasirox Revenue Market Share by Application (2021-2032)
- 6.2 Global Deferasirox Sales by Application
- 6.2.1 Global Deferasirox Sales by Application (2021 VS 2025 VS 2032)
- 6.2.2 Global Deferasirox Sales by Application (2021-2032) & (M Tablets)
- 6.2.3 Global Deferasirox Sales Market Share by Application (2021-2032)
- 6.3 Global Deferasirox Price by Application
7 Company Profiles
- 7.1 Novartis
- 7.1.1 Novartis Company Information
- 7.1.2 Novartis Business Overview
- 7.1.3 Novartis Deferasirox Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.1.4 Novartis Deferasirox Product Portfolio
- 7.1.5 Novartis Recent Developments
- 7.2 Cipla
- 7.2.1 Cipla Company Information
- 7.2.2 Cipla Business Overview
- 7.2.3 Cipla Deferasirox Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.2.4 Cipla Deferasirox Product Portfolio
- 7.2.5 Cipla Recent Developments
- 7.3 Natco Pharma
- 7.3.1 Natco Pharma Company Information
- 7.3.2 Natco Pharma Business Overview
- 7.3.3 Natco Pharma Deferasirox Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.3.4 Natco Pharma Deferasirox Product Portfolio
- 7.3.5 Natco Pharma Recent Developments
- 7.4 Sun Pharma
- 7.4.1 Sun Pharma Company Information
- 7.4.2 Sun Pharma Business Overview
- 7.4.3 Sun Pharma Deferasirox Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.4.4 Sun Pharma Deferasirox Product Portfolio
- 7.4.5 Sun Pharma Recent Developments
8 North America
- 8.1 North America Deferasirox Market Size by Type
- 8.1.1 North America Deferasirox Revenue by Type (2021-2032)
- 8.1.2 North America Deferasirox Sales by Type (2021-2032)
- 8.1.3 North America Deferasirox Price by Type (2021-2032)
- 8.2 North America Deferasirox Market Size by Application
- 8.2.1 North America Deferasirox Revenue by Application (2021-2032)
- 8.2.2 North America Deferasirox Sales by Application (2021-2032)
- 8.2.3 North America Deferasirox Price by Application (2021-2032)
- 8.3 North America Deferasirox Market Size by Country
- 8.3.1 North America Deferasirox Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 8.3.2 North America Deferasirox Sales by Country (2021 VS 2025 VS 2032)
- 8.3.3 North America Deferasirox Price by Country (2021-2032)
- 8.3.4 United States
- 8.3.5 Canada
- 8.3.6 Mexico
9 Europe
- 9.1 Europe Deferasirox Market Size by Type
- 9.1.1 Europe Deferasirox Revenue by Type (2021-2032)
- 9.1.2 Europe Deferasirox Sales by Type (2021-2032)
- 9.1.3 Europe Deferasirox Price by Type (2021-2032)
- 9.2 Europe Deferasirox Market Size by Application
- 9.2.1 Europe Deferasirox Revenue by Application (2021-2032)
- 9.2.2 Europe Deferasirox Sales by Application (2021-2032)
- 9.2.3 Europe Deferasirox Price by Application (2021-2032)
- 9.3 Europe Deferasirox Market Size by Country
- 9.3.1 Europe Deferasirox Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 9.3.2 Europe Deferasirox Sales by Country (2021 VS 2025 VS 2032)
- 9.3.3 Europe Deferasirox Price by Country (2021-2032)
- 9.3.4 Germany
- 9.3.5 France
- 9.3.6 U.K.
- 9.3.7 Italy
- 9.3.8 Russia
- 9.3.9 Spain
- 9.3.10 Netherlands
10 China
- 10.1 China Deferasirox Market Size by Type
- 10.1.1 China Deferasirox Revenue by Type (2021-2032)
- 10.1.2 China Deferasirox Sales by Type (2021-2032)
- 10.1.3 China Deferasirox Price by Type (2021-2032)
- 10.2 China Deferasirox Market Size by Application
- 10.2.1 China Deferasirox Revenue by Application (2021-2032)
- 10.2.2 China Deferasirox Sales by Application (2021-2032)
- 10.2.3 China Deferasirox Price by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Deferasirox Market Size by Type
- 11.1.1 Asia Deferasirox Revenue by Type (2021-2032)
- 11.1.2 Asia Deferasirox Sales by Type (2021-2032)
- 11.1.3 Asia Deferasirox Price by Type (2021-2032)
- 11.2 Asia Deferasirox Market Size by Application
- 11.2.1 Asia Deferasirox Revenue by Application (2021-2032)
- 11.2.2 Asia Deferasirox Sales by Application (2021-2032)
- 11.2.3 Asia Deferasirox Price by Application (2021-2032)
- 11.3 Asia Deferasirox Market Size by Country
- 11.3.1 Asia Deferasirox Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 11.3.2 Asia Deferasirox Sales by Country (2021 VS 2025 VS 2032)
- 11.3.3 Asia Deferasirox Price by Country (2021-2032)
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 India
- 11.3.7 Australia
- 11.3.8 Taiwan
- 11.3.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Deferasirox Market Size by Type
- 12.1.1 SAMEA Deferasirox Revenue by Type (2021-2032)
- 12.1.2 SAMEA Deferasirox Sales by Type (2021-2032)
- 12.1.3 SAMEA Deferasirox Price by Type (2021-2032)
- 12.2 SAMEA Deferasirox Market Size by Application
- 12.2.1 SAMEA Deferasirox Revenue by Application (2021-2032)
- 12.2.2 SAMEA Deferasirox Sales by Application (2021-2032)
- 12.2.3 SAMEA Deferasirox Price by Application (2021-2032)
- 12.3 SAMEA Deferasirox Market Size by Country
- 12.3.1 SAMEA Deferasirox Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 12.3.2 SAMEA Deferasirox Sales by Country (2021 VS 2025 VS 2032)
- 12.3.3 SAMEA Deferasirox Price by Country (2021-2032)
- 12.3.4 Brazil
- 12.3.5 Argentina
- 12.3.6 Chile
- 12.3.7 Colombia
- 12.3.8 Peru
- 12.3.9 Saudi Arabia
- 12.3.10 Israel
- 12.3.11 UAE
- 12.3.12 Turkey
- 12.3.13 Iran
- 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
- 13.1 Deferasirox Value Chain Analysis
- 13.1.1 Deferasirox Key Raw Materials
- 13.1.2 Raw Materials Key Suppliers
- 13.1.3 Manufacturing Cost Structure
- 13.1.4 Deferasirox Production Mode & Process
- 13.2 Deferasirox Sales Channels Analysis
- 13.2.1 Direct Comparison with Distribution Share
- 13.2.2 Deferasirox Distributors
- 13.2.3 Deferasirox Customers
14 Concluding Insights
15 Appendix
- 15.1 Reasons for Doing This Study
- 15.2 Research Methodology
- 15.3 Research Process
- 15.4 Authors List of This Report
- 15.5 Data Source
- 15.5.1 Secondary Sources
- 15.5.2 Primary Sources
- 15.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst